Logo Image

Shusen Wang

Articles by Shusen Wang

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri,Seock-Ah Im,Senia Pernas,Michelino De Laurentiis,Shusen Wang,Noelia Martínez Jañez,Giuliano Borges,David W. Cescon,Masaya Hattori,Yen-Shen Lu,Erika P. Hamilton, MD,Qingyuan Zhang,Junji Tsurutani,Kevin Kalinsky, MD, MS,Lu Xu,Neelima Denduluri,Binghe Xu,Barbara Pistilli

Latest Updated Articles